How to buy Innate Pharma S-A stock

Innate Pharma S.A is a biotechnology business based in the US. Innate Pharma S-A shares (IPHA) are listed on the NASDAQ and all prices are listed in US Dollars.

Innate Pharma S-A share price

Use our graph to track the performance of IPHA stocks over time.

Innate Pharma S-A shares at a glance

• Key figures

Information last updated 2021-04-15.

52-week range	USD$3.55 - USD$8.23
50-day moving average	USD$4.42
200-day moving average	USD$4.44
Wall St. target price	USD$7.35
PE ratio	13.6587
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Innate Pharma S-A shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Innate Pharma S-A stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Innate Pharma S.A by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Innate Pharma S-A under- or over-valued?

Valuing Innate Pharma S-A stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Innate Pharma S-A's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Innate Pharma S-A's P/E ratio

Innate Pharma S-A's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 14x. In other words, Innate Pharma S-A shares trade at around 14x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Innate Pharma S-A's EBITDA

Innate Pharma S-A's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$38.3 million.

The EBITDA is a measure of a Innate Pharma S-A's overall financial performance and is widely used to measure a its profitability.

Innate Pharma S-A financials

Revenue TTM	USD$70.5 million
Gross profit TTM	USD$11.8 million
Return on assets TTM	-3.27%
Return on equity TTM	-34.27%
Profit margin	-90.82%
Book value	N/A
Market capitalisation	USD$355.9 million

TTM: trailing 12 months

Shorting Innate Pharma S-A shares

There are currently 6,950 Innate Pharma S-A shares held short by investors – that's known as Innate Pharma S-A's "short interest". This figure is 7.5% down from 7,512 last month.

There are a few different ways that this level of interest in shorting Innate Pharma S-A shares can be evaluated.

Innate Pharma S-A's "short interest ratio" (SIR)

Innate Pharma S-A's "short interest ratio" (SIR) is the quantity of Innate Pharma S-A shares currently shorted divided by the average quantity of Innate Pharma S-A shares traded daily (recently around 6435.1851851852). Innate Pharma S-A's SIR currently stands at 1.08. In other words for every 100,000 Innate Pharma S-A shares traded daily on the market, roughly 1080 shares are currently held short.

However Innate Pharma S-A's short interest can also be evaluated against the total number of Innate Pharma S-A shares, or, against the total number of tradable Innate Pharma S-A shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Innate Pharma S-A's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Innate Pharma S-A shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Innate Pharma S-A shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Innate Pharma S-A.

Find out more about how you can short Innate Pharma S-A stock.

Innate Pharma S-A share dividends

We're not expecting Innate Pharma S-A to pay a dividend over the next 12 months.

Innate Pharma S-A share price volatility

Over the last 12 months, Innate Pharma S-A's shares have ranged in value from as little as $3.55 up to $8.23. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Innate Pharma S-A's is 0.2115. This would suggest that Innate Pharma S-A's shares are less volatile than average (for this exchange).

Innate Pharma S-A overview

Innate Pharma S. A. , a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal cancer, as well as head and neck cancer; Anti-Siglec-9, checkpoint inhibitor program, which is in preclinical stage for immuno-oncology; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; and Lacutamab (IPH4102), an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma. Its products also include IPH61, a bispecific NK cell engager, a preclinical solution for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, a program that is in preclinical trial to develop anti-MICA/B therapeutic antibody in oncology; Avdoralimab/IPH5401, a therapeutic antibody, which is in Phase II clinical trial that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils; IPH5201, a blocking antibody that is in Phase I clinical trial targeting the CD39 immunosuppressive pathway; and IPH5301, a CD-73-blocking antibody that is in preclinical trial for restoring a pro-inflammatory microenvironment. Innate Pharma S. A.

Frequently asked questions

• What percentage of Innate Pharma S-A is owned by insiders or institutions?

  Currently 1.551% of Innate Pharma S-A shares are held by insiders and 1.903% by institutions.

• When does the fiscal year end for Innate Pharma S-A?

  Innate Pharma S-A's fiscal year ends in December.

• Where is Innate Pharma S-A based?

  Innate Pharma S-A's address is: 117 Avenue de Luminy, Marseille, France, 13009

• What is Innate Pharma S-A's ISIN number?

  Innate Pharma S-A's international securities identification number is: US45781K2042

• What is Innate Pharma S-A's CUSIP number?

  Innate Pharma S-A's Committee on Uniform Securities Identification Procedures number is: 45781K204